Antisense Elements (Genetics)
- Name
- Antisense Elements (Genetics)
- Accession Number
- DBCAT001715
- Description
Nucleic acids which hybridize to complementary sequences in other target nucleic acids causing the function of the latter to be affected.
- Drugs
Drug Drug Description Mipomersen An oligonucleotide drug used for the treatment of homozygous familial hypercholesterolemia. Bevasiranib Investigated for use/treatment in macular degeneration and diabetic retinopathy. Fomivirsen Indicated for the local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS), when other therapy has been ineffective or is considered unsuitable [FDA Label, L1428]. Patisiran A transthyretin-directed small interfering RNA used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis. Oblimersen Not Annotated Inotersen An antisense oligonucleotide used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis. Inclisiran A PCSK9-targeting short interfering RNA (siRNA) that lowers plasma LDL-cholesterol levels. Revusiran Revusiran is under investigation in clinical trial NCT02319005 (ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)). Fitusiran Fitusiran is under investigation in clinical trial NCT02554773 (An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B). Golodirsen A drug used to treat certain mutations that cause Duchenne muscular dystrophy (DMD). Lumasiran Lumasiran is an interfering RNA that silences hydroxyacid oxidase 1 for the treatment of primary hypoxaluria type 1. - Drugs & Drug Targets